Recruiting
Phase 2

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06465186

Conditions

Non-alcoholic Fatty Liver Disease

Nonalcoholic Steatohepatitis

NAFLD

Metabolic Dysfunction-associated Steatotic Liver Disease

Metabolic Dysfunction-associated Steatohepatitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Efinopegdutide

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information